Company / Operating Cash Flow
Immunome Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$190.9M
FY2025
5-year range
-$190.9M / -$7.6M
FY2021-FY2025
Trend
-2422.7%
vs FY2024
Sector context
#169 of 216
Health Care
What the data says
Operating Cash Flow changed -2423% YoY in FY2025, a notable deviation from the 6-year average annual change of -414%.
Based on SEC 10-K filings.
-$191M in FY2025.
Declined from -$29M to -$191M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 216This company -$190.9M Sector average $659.0M
▼
-129.0% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 2422.7% year-over-year.
- Ranks #169 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 4.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$190.9M | -2422.7% |
| FY2024 | -$7.6M | +73.6% |
| FY2023 | -$28.7M | +0.0% |
| FY2022 | -$28.7M | -57.4% |
| FY2021 | -$18.2M | -50.2% |
| FY2020 | -$12.1M | -26.4% |
| FY2019 | -$9.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026